Jose L Estrada1, Greg Martens1, Ping Li1, Andrew Adams2,3, Kenneth A Newell3, Mandy L Ford3, James R Butler1, Richard Sidner1, Matt Tector4, Joseph Tector1,5. 1. Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA. 2. Yerkes National Primate Research Center, Atlanta, GA, USA. 3. Emory Transplant Center and Department of Surgery, Emory University, Atlanta, GA, USA. 4. Department of Surgery, Indiana University Health, Indianapolis, IN, USA. 5. IU Health Transplant Institute, Indianapolis, IN, USA.
Abstract
BACKGROUND: Simultaneous inactivation of pig GGTA1 and CMAH genes eliminates carbohydrate xenoantigens recognized by human antibodies. The β4GalNT2 glycosyltransferase may also synthesize xenoantigens. To further characterize glycan-based species incompatibilities, we examined human and non-human primate antibody binding to cells derived from genetically modified pigs lacking these carbohydrate-modifying genes. METHODS: The Cas9 endonuclease and gRNA were used to create pigs lacking GGTA1, GGTA1/CMAH, or GGTA1/CMAH/β4GalNT2 genes. Peripheral blood mononuclear cells were isolated from these animals and examined for binding to IgM and IgG from humans, rhesus macaques, and baboons. RESULTS: Cells from GGTA1/CMAH/β4GalNT2 deficient pigs exhibited reduced human IgM and IgG binding compared to cells lacking both GGTA1 and CMAH. Non-human primate antibody reactivity with cells from the various pigs exhibited a slightly different pattern of reactivity than that seen in humans. Simultaneous inactivation of the GGTA1 and CMAH genes increased non-human primate antibody binding compared to cells lacking either GGTA1 only or to those deficient in GGTA1/CMAH/β4GalNT2. CONCLUSIONS: Inactivation of the β4GalNT2 gene reduces human and non-human primate antibody binding resulting in diminished porcine xenoantigenicity. The increased humoral immunity of non-human primates toward GGTA1-/CMAH-deficient cells compared to pigs lacking either GGTA1 or GGTA1/CMAH/β4GalNT2 highlights the complexities of carbohydrate xenoantigens and suggests potential limitations of the non-human primate model for examining some genetic modifications. The progressive reduction of swine xenoantigens recognized by human immunoglobulin through inactivation of pig GGTA1/CMAH/β4GalNT2 genes demonstrates that the antibody barrier to xenotransplantation can be minimized by genetic engineering.
BACKGROUND: Simultaneous inactivation of pigGGTA1 and CMAH genes eliminates carbohydrate xenoantigens recognized by human antibodies. The β4GalNT2 glycosyltransferase may also synthesize xenoantigens. To further characterize glycan-based species incompatibilities, we examined human and non-human primate antibody binding to cells derived from genetically modified pigs lacking these carbohydrate-modifying genes. METHODS: The Cas9 endonuclease and gRNA were used to create pigs lacking GGTA1, GGTA1/CMAH, or GGTA1/CMAH/β4GalNT2 genes. Peripheral blood mononuclear cells were isolated from these animals and examined for binding to IgM and IgG from humans, rhesus macaques, and baboons. RESULTS: Cells from GGTA1/CMAH/β4GalNT2 deficient pigs exhibited reduced human IgM and IgG binding compared to cells lacking both GGTA1 and CMAH. Non-human primate antibody reactivity with cells from the various pigs exhibited a slightly different pattern of reactivity than that seen in humans. Simultaneous inactivation of the GGTA1 and CMAH genes increased non-human primate antibody binding compared to cells lacking either GGTA1 only or to those deficient in GGTA1/CMAH/β4GalNT2. CONCLUSIONS: Inactivation of the β4GalNT2 gene reduces human and non-human primate antibody binding resulting in diminished porcine xenoantigenicity. The increased humoral immunity of non-human primates toward GGTA1-/CMAH-deficient cells compared to pigs lacking either GGTA1 or GGTA1/CMAH/β4GalNT2 highlights the complexities of carbohydrate xenoantigens and suggests potential limitations of the non-human primate model for examining some genetic modifications. The progressive reduction of swine xenoantigens recognized by human immunoglobulin through inactivation of pigGGTA1/CMAH/β4GalNT2 genes demonstrates that the antibody barrier to xenotransplantation can be minimized by genetic engineering.
Authors: Zheng-Yu Wang; Christopher Burlak; Jose L Estrada; Ping Li; Matthew F Tector; A Joseph Tector Journal: Xenotransplantation Date: 2014-07-02 Impact factor: 3.907
Authors: Wenfang Tan; Daniel F Carlson; Cheryl A Lancto; John R Garbe; Dennis A Webster; Perry B Hackett; Scott C Fahrenkrug Journal: Proc Natl Acad Sci U S A Date: 2013-09-06 Impact factor: 11.205
Authors: C Burlak; L L Paris; A J Lutz; R A Sidner; J Estrada; P Li; M Tector; A J Tector Journal: Am J Transplant Date: 2014-06-06 Impact factor: 8.086
Authors: Luz M Reyes; Jose L Estrada; Zheng Yu Wang; Rachel J Blosser; Rashod F Smith; Richard A Sidner; Leela L Paris; Ross L Blankenship; Caitlin N Ray; Aaron C Miner; Matthew Tector; A Joseph Tector Journal: J Immunol Date: 2014-10-22 Impact factor: 5.422
Authors: Ping Li; Jose L Estrada; Christopher Burlak; Jessica Montgomery; James R Butler; Rafael M Santos; Zheng-Yu Wang; Leela L Paris; Ross L Blankenship; Susan M Downey; Matthew Tector; A Joseph Tector Journal: Xenotransplantation Date: 2014-09-02 Impact factor: 3.907
Authors: Kristin M Whitworth; Kiho Lee; Joshua A Benne; Benjamin P Beaton; Lee D Spate; Stephanie L Murphy; Melissa S Samuel; Jiude Mao; Chad O'Gorman; Eric M Walters; Clifton N Murphy; John Driver; Alan Mileham; David McLaren; Kevin D Wells; Randall S Prather Journal: Biol Reprod Date: 2014-08-06 Impact factor: 4.285
Authors: Ajay K Israni; Nicholas Salkowski; Sally Gustafson; Jon J Snyder; John J Friedewald; Richard N Formica; Xinyue Wang; Eugene Shteyn; Wida Cherikh; Darren Stewart; Ciara J Samana; Adrine Chung; Allyson Hart; Bertram L Kasiske Journal: J Am Soc Nephrol Date: 2014-05-15 Impact factor: 10.121
Authors: Guerard W Byrne; Zeji Du; Paul Stalboerger; Heide Kogelberg; Christopher G A McGregor Journal: Xenotransplantation Date: 2014-09-01 Impact factor: 3.907
Authors: James R Butler; Gregory R Martens; Jose L Estrada; Luz M Reyes; Joseph M Ladowski; Cesare Galli; Andrea Perota; Conor M Cunningham; Matthew Tector; A Joseph Tector Journal: Transgenic Res Date: 2016-04-21 Impact factor: 2.788
Authors: K P Samy; R P Davis; Q Gao; B M Martin; M Song; J Cano; A B Farris; A McDonald; E K Gall; C R Dove; F V Leopardi; T How; K D Williams; G R Devi; B H Collins; A D Kirk Journal: Am J Transplant Date: 2017-12-28 Impact factor: 8.086
Authors: Joseph M Ladowski; Gregory R Martens; Luz M Reyes; Zheng-Yu Wang; Devin E Eckhoff; Vera Hauptfeld-Dolejsek; Matt Tector; A Joseph Tector Journal: J Immunol Date: 2018-03-14 Impact factor: 5.422